Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CJC-1295 vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CJC-1295 has stronger documented evidence (Anecdotal + Phase 2 (DAC)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, CJC-1295 is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CJC-1295

Anecdotal + Phase 2 (DAC)

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

CJC-1295 CJC-1295 + Ipamorelin
Class GHRH analog (no-DAC or DAC forms) GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route SC injection SC injection
Half-life No-DAC ~30 min / DAC ~8 days CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier Anecdotal + Phase 2 (DAC) Anecdotal + Animal Studies
Research depth 44 indexed (PubMed 34 · CT 1 · EPMC 9) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Compounding Restricted Compounding Restricted
Reported risks Water retention; numbness/tingling; elevated IGF-1; injection site reactions Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CJC-1295 or CJC-1295 + Ipamorelin?

CJC-1295 has stronger documented evidence (Anecdotal + Phase 2 (DAC)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, CJC-1295 is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between CJC-1295 and CJC-1295 + Ipamorelin?

CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: CJC-1295, SC injection; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, CJC-1295 or CJC-1295 + Ipamorelin?

CJC-1295 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, CJC-1295 or CJC-1295 + Ipamorelin?

Neither CJC-1295 nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; CJC-1295 + Ipamorelin, Compounding Restricted. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are CJC-1295 and CJC-1295 + Ipamorelin ever combined?

CJC-1295 and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…